Genmab technology to put pressure on copyists
![](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article5717140.ece/ALTERNATES/schema-16_9/Genmab_logo_silver_on_green.jpg)
Expectations are great for the HexaBody platform, designed to increase the effect of antibody treatments. Current blockbusters, and even abandoned candidate drugs, could turn out to be a future goldmine for the Danish developer of the technology, Genmab.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab to expand Arzerra
For abonnenter
Genmab-CEO: Drug could be ready in 2016
For abonnenter